IBRX | tickerfilter.com

Fundamental analysis

28%

Profitability 25%

Dept financing 25%

Liquidity 55%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.47%

1 Month

-15.68%

3 Months

-34.95%

6 Months

-61.95%

1 Year

-35.81%

2 Year

-49.37%

Key data

Stock price

$2.41

P/E Ratio

0.00

DAY RANGE

$2.41 - $2.42

EPS

-$0.95

52 WEEK RANGE

$2.60 - $10.53

52 WEEK CHANGE

-$35.81

MARKET CAP

2.591 B

YIELD

N/A

SHARES OUTSTANDING

696.533 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

2.46

PUBLIC FLOAT

AVERAGE 10 VOLUME

$4,829,003

AVERAGE 30 VOLUME

$5,768,080

Company detail

CEO: Richard Adcock
Region: US
Website: immunitybio.com
Employees: 590
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.

IBRX - ImmunityBio, Inc.